Claudin 18.2-a FAST-moving target in gastric cancer?
- PMID: 33677015
- DOI: 10.1016/j.annonc.2021.02.021
Claudin 18.2-a FAST-moving target in gastric cancer?
Conflict of interest statement
Disclosure IC has received advisory board fees from Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte and Astella; research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology and honorarium from Eli-Lilly. AA has declared no conflicts of interest.
Comment on
-
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.Ann Oncol. 2021 May;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19. Ann Oncol. 2021. PMID: 33610734 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
